Femasys (NASDAQ:FEMY) Research Coverage Started at Lake Street Capital

Lake Street Capital initiated coverage on shares of Femasys (NASDAQ:FEMY) in a research note published on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $1.50 price objective on the stock.

A number of other research firms have also recently commented on FEMY. Wall Street Zen cut Femasys from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Laidlaw assumed coverage on shares of Femasys in a research note on Thursday, November 20th. They set a “buy” rating and a $6.50 price target on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Femasys in a report on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Femasys presently has a consensus rating of “Moderate Buy” and an average target price of $5.50.

Femasys Price Performance

FEMY stock opened at $0.53 on Tuesday. The stock’s 50 day moving average price is $0.57 and its 200 day moving average price is $0.62. The firm has a market cap of $30.88 million, a P/E ratio of -0.73 and a beta of -2.53. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.61 and a current ratio of 1.16. Femasys has a 1 year low of $0.31 and a 1 year high of $1.76.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Kovack Advisors Inc. acquired a new stake in shares of Femasys in the fourth quarter worth approximately $27,000. Osaic Holdings Inc. purchased a new position in Femasys during the second quarter worth approximately $45,000. HRT Financial LP acquired a new position in shares of Femasys in the 4th quarter valued at $30,000. Cetera Investment Advisers acquired a new position in shares of Femasys in the 4th quarter valued at $36,000. Finally, State Street Corp grew its stake in shares of Femasys by 43.5% during the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after buying an additional 24,500 shares during the period. 65.27% of the stock is currently owned by hedge funds and other institutional investors.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.